Cost-savings of adalimumab in hidradenitis suppurativa: a retrospective analysis of a real-world cohort.

摘要: Background The introduction of adalimumab in the management hidradenitis suppurativa (HS) raises questions regarding cost-efficacy treatment. Objectives To explore treatment with anti-tumour necrosis factor (TNF) agents a real-world cohort. Methods Patients Hurley stage II and III HS ≥ 1 year follow-up at least three visits per from September 2003 to December 2016 were analysed. Patient divided into two categories - for blocking TNF or other therapies. cost exacerbations was calculated based on items provided current price lists by national health insurance agency cases hospitalization. Effectiveness anti-TNF assessing containment exacerbations. primary study end point cost-savings achieved using agents. Results Overall, 1211 patient 250 patients Total found 25·1% involving therapies 63·4% visit receiving vs. €178·92. odds ratio total among 4·86 6·03, respectively (P = 0·466). Treatment an independent variable affecting annual as shown two-way analysis variance. In HS, mean €8309·60 under compared €3264·20 0·004). Conclusions achieves significant cost-benefit through efficacy similar both disease stages.